Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reforms in Pharma on Snail Pace (India)

This article was originally published in PharmAsia News

Executive Summary

India-based pharmaceutical companies are calling on government officials to reform the country's price control policy. They claim the government does not take into account the costs of packaging when establishing price restrictions on drugs. Drug manufacturers say without this consideration, it is not cost effective to produce packaging necessary to discourage the sale of substandard imitation drugs. This leaves pharmaceutical companies with a major dilemma. They can either foot the cost of packaging or risk a glut of fraudulent drugs flooding the market. Representatives for India's pharmaceutical companies worry that to avoid this quandary some manufacturers will stop making price controlled products. Unfortunately, the 75 drugs on India's price controlled list, like Iron and Vitamin A supplements, are necessary for the health of the country's population. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel